Keros Therapeutics, INC Schedule 13G passive stakes

BlackRock, Inc. has reported beneficial ownership of 10.1% of Keros Therapeutics, Inc.'s common stock as of March 31, 2026.

The Vanguard Group reported 0% beneficial ownership in Keros Therapeutics Inc. following an internal realignment.

The Vanguard Group has reported a 5% beneficial ownership stake in Keros Therapeutics Inc., holding 1,525,355 shares of common stock.

ExodusPoint Capital Management, along with its affiliates, has reported a 6.3% beneficial ownership stake in Keros Therapeutics, Inc., totaling 1,907,899 shares.

D. E. Shaw & Co. entities and David E. Shaw have reported beneficial ownership of 5.1% of Keros Therapeutics, Inc.'s common stock.

Tang Capital Management and affiliated entities have reported a 7.9% passive ownership stake in Keros Therapeutics, Inc. as of October 15, 2025.

A group of investment entities and individuals led by Eli Samaha, including Madison Avenue Partners and Madison Avenue International, has disclosed a passive beneficial ownership of 6.4% in Keros Therapeutics, Inc.

JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a 0.2% beneficial ownership stake in Keros Therapeutics, Inc. as of April 30, 2025.

JPMorgan Chase & Co. has filed a Schedule 13G, revealing a 6.3% beneficial ownership stake in Keros Therapeutics, Inc. as of March 31, 2025.

The Vanguard Group has disclosed a 6.32% beneficial ownership stake in Keros Therapeutics Inc, holding 2,566,321 shares of common stock as of March 31, 2025.

Alkeon Capital Management LLC and its founder, Panayotis D. Sparaggis, have disclosed a beneficial ownership of 2.7% in Keros Therapeutics, Inc. as of December 31, 2024.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 1.7% of Keros Therapeutics Inc.'s common stock as of January 31, 2025.